<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>International Journal of Preventive Medicine (Int J Prev Med)</JournalTitle><Issn>2008-7802</Issn><Volume>14</Volume><Issue>6</Issue><PubDate PubStatus="epublish"><Year>2023</Year><Month>07</Month><Day>30</Day></PubDate></Journal><title locale="en_US">How Long that a SARS‑CoV‑2 Variant Delay Impacts Required Period to Achieve Herd Immunity?</title><FirstPage>2839</FirstPage><LastPage>2839</LastPage><Language>EN</Language><AuthorList><Author><affiliation locale="en_US">Private Academic Consultant, Bangkok</affiliation></Author><Author><affiliation locale="en_US">Honorary Professor, Dr DY Patil Vidhyapeeth, Pune, Maharashtra</affiliation></Author></AuthorList><History><PubDate PubStatus="received"><Year>2023</Year><Month>07</Month><Day>29</Day></PubDate></History><abstract locale="en_US">Dear Editor, The coronavirus disease (COVID‑19) vaccine is the present preventive tool for COVID‑19 containment. Mass immunization is required for achieving herd immunity. If herd immunity is reached, a successful COVID‑19 containment is expected.[1,2] In general, the targeted population size that herd immunity will achieve is mainly based on the basic reproduction number and is generally estimated as 75%.[1,2] Regarding the required period to achieve the impact of herd immunity depends on many facts including the targeted population size (unit: %), base local infection prevalence (unit: %), vaccination rate (unit: %), efficacy of vaccine (unit: %), and monthly infection rate (unit: %).</abstract><web_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2839</web_url><pdf_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2839/717718717</pdf_url></Article></Articles>
